251 related articles for article (PubMed ID: 21691871)
21. Gastric Neuroendocrine Tumors (Carcinoids).
Gluckman CR; Metz DC
Curr Gastroenterol Rep; 2019 Mar; 21(4):13. PubMed ID: 30868284
[TBL] [Abstract][Full Text] [Related]
22. Recurrent gastric neuroendocrine tumors treated with total gastrectomy.
Jung M; Kim JW; Jang JY; Chang YW; Park SH; Kim YH; Kim YW
World J Gastroenterol; 2015 Dec; 21(46):13195-200. PubMed ID: 26675502
[TBL] [Abstract][Full Text] [Related]
23. [Neuroendocrine tumors of the stomach. Pathogenesis, classification and clinical aspects].
Bordi C; Azzoni C; D'Adda T; Caruana P; Carlinfante G
Pathologe; 1997 Jul; 18(4):313-21. PubMed ID: 9380606
[TBL] [Abstract][Full Text] [Related]
24. Gastric neuroendocrine tumors in our institutions according to the WHO 2010 classification.
Endo S; Dousei T; Yoshikawa Y; Hatanaka N; Taniyama K; Yamauchi A; Kamiike W; Nishijima J
Int Surg; 2012; 97(4):335-9. PubMed ID: 23294075
[TBL] [Abstract][Full Text] [Related]
25. [Early gastric cancer--or not].
Burri E; Nüesch R; Lugli A; Noll P; Vavricka SR
Praxis (Bern 1994); 2008 Dec; 97(25):1351-5. PubMed ID: 19085848
[TBL] [Abstract][Full Text] [Related]
26. Effects of tumor types on treatment strategy formulation and prognostic evaluation of gastric neuroendocrine tumors.
Jiao X; Wang Z; Peng X; Zhang L; Zhou L
Future Oncol; 2020 Oct; 16(28):2197-2207. PubMed ID: 32687408
[No Abstract] [Full Text] [Related]
27. Comparison of World Health Organization 2000/2004 and World Health Organization 2010 classifications for gastrointestinal and pancreatic neuroendocrine tumors.
Pasaoglu E; Dursun N; Ozyalvacli G; Hacihasanoglu E; Behzatoglu K; Calay O
Ann Diagn Pathol; 2015 Apr; 19(2):81-7. PubMed ID: 25702616
[TBL] [Abstract][Full Text] [Related]
28. A rare case of an enterochromaffin-like neuroendocrine tumor associated with parietal cell dysfunction treated using endoscopic submucosal dissection.
Shiroma S; Higuchi K; Ota H; Umeno J; Ishioka M; Hirasawa T; Kuba H; Ono T; Uchima R; Nagamura R
Clin J Gastroenterol; 2022 Dec; 15(6):1041-1047. PubMed ID: 36125703
[TBL] [Abstract][Full Text] [Related]
29. Re-evaluation of cases with gastroenteropancreatic neuroendocrine tumors between 2004 and 2012 according to the 2010 criteria.
Ozkara S; Aker F; Yesil A; Senates E; Canbey C; Yitik A; Gonen C
Hepatogastroenterology; 2013 Oct; 60(127):1665-72. PubMed ID: 24627925
[TBL] [Abstract][Full Text] [Related]
30. The role of 68-Ga-DOTATOC CT-PET in surgical tactic for gastric neuroendocrine tumors treatment: our experience: a case report.
Cavallaro A; Zanghì A; Cavallaro M; Lo Menzo E; Di Carlo I; Di Vita M; Cardì F; Piccolo G; Di Mattia P; Cappellani A
Int J Surg; 2014; 12 Suppl 1():S225-31. PubMed ID: 24862665
[TBL] [Abstract][Full Text] [Related]
31. Histologic characterization and improved prognostic evaluation of 209 gastric neuroendocrine neoplasms.
La Rosa S; Inzani F; Vanoli A; Klersy C; Dainese L; Rindi G; Capella C; Bordi C; Solcia E
Hum Pathol; 2011 Oct; 42(10):1373-84. PubMed ID: 21531442
[TBL] [Abstract][Full Text] [Related]
32. Clinicopathological features and outcome of type 3 gastric neuroendocrine tumours.
Min BH; Hong M; Lee JH; Rhee PL; Sohn TS; Kim S; Kim KM; Kim JJ
Br J Surg; 2018 Oct; 105(11):1480-1486. PubMed ID: 29893418
[TBL] [Abstract][Full Text] [Related]
33. Recent updates on grading and classification of neuroendocrine tumors.
Kim JY; Hong SM; Ro JY
Ann Diagn Pathol; 2017 Aug; 29():11-16. PubMed ID: 28807335
[TBL] [Abstract][Full Text] [Related]
34. Selective Resection of Type 1 Gastric Neuroendocrine Neoplasms and the Risk of Progression in an Endoscopic Surveillance Programme.
Chin JL; O'Connell J; Muldoon C; Swan N; Reynolds JV; Ravi N; Geoghegan J; Conlon KC; O'Shea D; O'Toole D
Dig Surg; 2021; 38(1):38-45. PubMed ID: 33260173
[TBL] [Abstract][Full Text] [Related]
35. Comparison of WHO 2000 and WHO 2010 classifications of gastroenteropancreatic neuroendocrine tumors.
Karakuş E; Helvacı A; Ekinci O; Dursun A
Turk J Gastroenterol; 2014 Feb; 25(1):81-7. PubMed ID: 24918137
[TBL] [Abstract][Full Text] [Related]
36. [Minimally invasive options for gastric tumors].
Bernhardt J; Ludwig K; Ptok H; Wilhelm L; Stier A; Heidecke CD
Zentralbl Chir; 2003 Jul; 128(7):566-72. PubMed ID: 12884143
[TBL] [Abstract][Full Text] [Related]
37. Influence of hypergastrinemia secondary to long-term proton pump inhibitor treatment on ECL cell tumorigenesis in human gastric mucosa.
Tatsuguchi A; Hoshino S; Kawami N; Gudis K; Nomura T; Shimizu A; Iwakiri K
Pathol Res Pract; 2020 Oct; 216(10):153113. PubMed ID: 32853950
[TBL] [Abstract][Full Text] [Related]
38. Review of the pathogenesis, diagnosis, and management of type I gastric carcinoid tumor.
Zhang L; Ozao J; Warner R; Divino C
World J Surg; 2011 Aug; 35(8):1879-86. PubMed ID: 21559999
[TBL] [Abstract][Full Text] [Related]
39. Five-year follow-up of patients treated for 1 year with octreotide long-acting release for enterochromaffin-like cell carcinoids.
Jianu CS; Fossmark R; Syversen U; Hauso Ø; Fykse V; Waldum HL
Scand J Gastroenterol; 2011 Apr; 46(4):456-63. PubMed ID: 21133821
[TBL] [Abstract][Full Text] [Related]
40. Neuroendocrine pathology of the stomach: the Parma contribution.
Bordi C
Endocr Pathol; 2014 Jun; 25(2):171-80. PubMed ID: 24782101
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
